☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
~$2B
AbbVie to License I-Mab's Lemzoparlimab (TJC4) for ~$2B
September 4, 2020
CSL Behring to Acquire uniQure' Hemophilia B Candidate (AMT-061) for ~$2B
June 25, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.
